(Q40249947)

18 September 2017

title

Preparation and in vitro analysis of microcapsule thalidomide formulation for targeted suppression of TNF-alpha (English)

1 reference

18 September 2017

0 references

Terrence Metz

1

1 reference

18 September 2017

Tasima Haque

2

1 reference

18 September 2017

Hongmei Chen

3

1 reference

18 September 2017

Satya Prakash

4

1 reference

18 September 2017

Devendra Amre

5

1 reference

18 September 2017

Sujata K Das

6

1 reference

18 September 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

18 September 2017

1 reference

18 September 2017

volume

13

1 reference

18 September 2017

issue

5

1 reference

18 September 2017

page(s)

331-337

1 reference

Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease

18 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

Artificial cells, encapsulation, and immobilization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

Therapeutic applications of polymeric artificial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

Thalidomide and its derivatives: emerging from the wilderness

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

The epidemiology and the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

New developments in the treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

Strategies for targeting tumour necrosis factor in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

Incidence of inflammatory bowel disease in Italy: a nationwide population-based study. Gruppo Italiano per lo Studio del Colon e del Retto (GISC)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

Lung toxicity due to thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10717540500466097

10.1080/10717540500466097

21 January 2018

Identifiers

DOI

1 reference

release_tqwrv2sx5zclfoo5s3vdfonjmy

18 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tqwrv2sx5zclfoo5s3vdfonjmy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference